{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T04:47:58Z","timestamp":1789274878732,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T00:00:00Z","timestamp":1616803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T00:00:00Z","timestamp":1616803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s00415-021-10523-8","type":"journal-article","created":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T09:02:39Z","timestamp":1616835759000},"page":"3789-3798","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study"],"prefix":"10.1007","volume":"268","author":[{"given":"Marta","family":"Torres-Ferr\u00fas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor J.","family":"Gallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Alpuente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Caronna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eulalia","family":"Gine-Cipres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Pozo-Rosich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,27]]},"reference":[{"issue":"22","key":"10523_CR1","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y, Broessner G, Bonner JH, Zhang F et al (2017) A controlled trial of erenumab for episodic migraine. N Engl J Med 377(22):2123\u20132132","journal-title":"N Engl J Med"},{"issue":"22","key":"10523_CR2","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T et al (2017) Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 377(22):2113\u20132122","journal-title":"N Engl J Med"},{"issue":"9","key":"10523_CR3","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","volume":"75","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR (2018) Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial. JAMA Neurol 75(9):1080\u20131088","journal-title":"JAMA Neurol"},{"issue":"19","key":"10523_CR4","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","volume":"319","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T et al (2018) Effect of Fremanezumab compared with placebo for prevention of episodic migraine a randomized clinical trial. JAMA 319(19):1999\u20132008","journal-title":"JAMA"},{"issue":"24","key":"10523_CR5","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK (2018) Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled regain study. Neurology 91(24):e2211\u2013e2221","journal-title":"Neurology"},{"issue":"13","key":"10523_CR6","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","volume":"94","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J et al (2020) Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology 94(13):e1365\u2013e1377","journal-title":"Neurology"},{"issue":"8","key":"10523_CR7","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1177\/0333102418779543","volume":"38","author":"V Skljarevski","year":"2018","unstructured":"Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim B-K, Yang JY (2018) Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia 38(8):1442\u20131454","journal-title":"Cephalalgia"},{"issue":"6","key":"10523_CR8","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","volume":"38","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V et al (2018) ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 38(6):1026\u20131037","journal-title":"Cephalalgia"},{"key":"10523_CR9","first-page":"1","volume":"2","author":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios","year":"2019","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (2019) Informe de posicionamiento terap\u00e9utico. Erenumab 2:1\u20138","journal-title":"Erenumab"},{"issue":"4","key":"10523_CR10","first-page":"1","volume":"20","author":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios","year":"2019","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (2019) Informe de Posicionamiento. Galcanezumab 20(4):1\u201311","journal-title":"Galcanezumab"},{"issue":"1","key":"10523_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-020-01130-5","volume":"21","author":"S Sacco","year":"2020","unstructured":"Sacco S, Sacco S, Braschinsky M, Ducros A, Lampl C, Little P et al (2020) European headache federation consensus on the definition of resistant and refractory migraine. J Headache Pain 21(1):1\u201312","journal-title":"J Headache Pain"},{"issue":"10210","key":"10523_CR12","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/S0140-6736(19)32504-8","volume":"394","author":"A Charles","year":"2019","unstructured":"Charles A, Pozo-Rosich P (2019) Targeting calcitonin gene-related peptide: a new era in migraine therapy. Lancet (London, England) 394(10210):1765\u20131774","journal-title":"Lancet (London, England)"},{"issue":"10","key":"10523_CR13","first-page":"1","volume":"5","author":"JL Brandes","year":"2019","unstructured":"Brandes JL, Diener H, Dolezil D, Freeman MC, Mcallister PJ, Winner P et al (2019) The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving \u226550%, \u226575%, and 100% response. Cephalalgia 5(10):1\u201311","journal-title":"Cephalalgia"},{"issue":"9","key":"10523_CR14","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1111\/head.13929","volume":"60","author":"G Broessner","year":"2020","unstructured":"Broessner G, Reuter U, Bonner JH, Dodick DW, Hallstr\u00f6m Y, Picard H et al (2020) The spectrum of response to erenumab in patients with episodic migraine and subgroup analysis of patients achieving \u226550%, \u226575%, and 100% response. Headache 60(9):2026\u20132040","journal-title":"Headache"},{"issue":"1","key":"10523_CR15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s10194-018-0951-2","volume":"19","author":"S F\u00f6rderreuther","year":"2018","unstructured":"F\u00f6rderreuther S, Zhang Q, Stauffer VL, Aurora SK, L\u00e1inez MJA (2018) Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies. J Headache Pain 19(1):121","journal-title":"J Headache Pain"},{"issue":"18","key":"10523_CR16","first-page":"1","volume":"6736","author":"U Reuter","year":"2018","unstructured":"Reuter U, Goadsby PJ, Lanteri-minet M, Wen S, Hours-zesiger P, Ferrari MD et al (2018) Articles efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful\u202f: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet 6736(18):1\u20139","journal-title":"Lancet"},{"issue":"10","key":"10523_CR17","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","volume":"19","author":"WM Mulleners","year":"2020","unstructured":"Mulleners WM, Kim B-K, L\u00e1inez MJA, Lanteri-Minet M, Pozo-Rosich P, Wang S et al (2020) Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 19(10):814\u2013825","journal-title":"Lancet Neurol"},{"issue":"10203","key":"10523_CR18","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","volume":"394","author":"MD Ferrari","year":"2019","unstructured":"Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R et al (2019) Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet (London, England) 394(10203):1030\u20131040","journal-title":"Lancet (London, England)"},{"issue":"1","key":"10523_CR19","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1212\/WNL.56.suppl_1.S20","volume":"56","author":"WF Stewart","year":"2001","unstructured":"Stewart WF, Lipton RB, Dowson AJ, Sawyer J (2001) Development and testing of the migraine disability assessment (MIDAS) questionnaire to assess headache-related disability. Neurology 56(1):S20\u2013S28","journal-title":"Neurology"},{"issue":"8","key":"10523_CR20","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1023\/A:1026119331193","volume":"12","author":"M Kosinski","year":"2003","unstructured":"Kosinski M, Bayliss MS, Bjorner JB, Ware JEJ, Garber WH, Batenhorst A et al (2003) A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res 12(8):963\u2013974","journal-title":"Qual Life Res"},{"issue":"3","key":"10523_CR21","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1046\/j.1526-4610.2000.00030.x","volume":"40","author":"BC Martin","year":"2000","unstructured":"Martin BC, Pathak DS, Sharfman MI, Adelman JU, Taylor F, Kwong WJ et al (2000) Validity and reliability of the migraine-specific quality of life questionnaire (MSQ Version 21). Headache 40(3):204\u2013215","journal-title":"Headache"},{"issue":"6","key":"10523_CR22","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1037\/0022-006X.56.6.893","volume":"56","author":"AT Beck","year":"1988","unstructured":"Beck AT, Epstein N, Brown G, Steer RA (1988) An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 56(6):893\u2013897","journal-title":"J Consult Clin Psychol"},{"key":"10523_CR23","volume-title":"Manual for the Beck Depression Inventory-II","author":"AT Beck","year":"1996","unstructured":"Beck AT, Steer RA, Brown GK (1996) Manual for the Beck Depression Inventory-II. Psychological Corporation"},{"issue":"9","key":"10523_CR24","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1177\/0333102411408359","volume":"31","author":"R Gil-Gouveia","year":"2011","unstructured":"Gil-Gouveia R, Oliveira AG, Martins IP (2011) A subjective cognitive impairment scale for migraine attacks The MIG-SCOG: development and validation. Cephalalgia 31(9):984\u2013991","journal-title":"Cephalalgia"},{"key":"10523_CR25","unstructured":"Team RC (2013) R: A language and environment for statistical computing."},{"issue":"10","key":"10523_CR26","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1177\/0333102418788347","volume":"38","author":"M Ashina","year":"2018","unstructured":"Ashina M, Tepper S, Brandes JL, Reuter U, Boudreau G, Dolezil D et al (2018) Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia 38(10):1611\u20131621","journal-title":"Cephalalgia"},{"issue":"10161","key":"10523_CR27","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","volume":"392","author":"U Reuter","year":"2018","unstructured":"Reuter U, Goadsby PJ, Lanteri-minet M, Wen S, Hours-zesiger P, Ferrari MD et al (2018) Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet 392(10161):2280\u20132287","journal-title":"Lancet"},{"issue":"8","key":"10523_CR28","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1177\/0333102419847957","volume":"39","author":"DD Ruff","year":"2019","unstructured":"Ruff DD, Ford JH, Tockhorn-heidenreich A, Sexson M, Govindan S, Pearlman EM et al (2019) Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure. Cephalalgia 39(8):931\u2013944","journal-title":"Cephalalgia"},{"issue":"7","key":"10523_CR29","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1177\/0333102419835459","volume":"39","author":"PJ Goadsby","year":"2019","unstructured":"Goadsby PJ, Paemeleire K, Broessner G, Brandes J, Klatt J, Zhang F et al (2019) Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia 39(7):817\u2013826","journal-title":"Cephalalgia"},{"issue":"1","key":"10523_CR30","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s10194-020-01143-0","volume":"21","author":"A Russo","year":"2020","unstructured":"Russo A, Silvestro M, Scotto F, Trojsi F, Bisecco A, Bonavita S et al (2020) Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments\u202f: a comprehensive real-world experience. J Headache Pain 21(1):69","journal-title":"J Headache Pain"},{"issue":"Suppl 2","key":"10523_CR31","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s10072-020-04669-y","volume":"41","author":"F Vernieri","year":"2020","unstructured":"Vernieri F, Altamura C, Aurilia C, Brunelli N, Egeo G, Fofi L et al (2020) Effectiveness, safety and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study). Neurol Sci 41(Suppl 2):487\u2013488","journal-title":"Neurol Sci"},{"issue":"1","key":"10523_CR32","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s10194-020-01151-0","volume":"21","author":"A Scheffler","year":"2020","unstructured":"Scheffler A, Messel O, Wurthmann S, Nsaka M, Kleinschnitz C, Glas M et al (2020) Erenumab in highly therapy-refractory migraine patients: first German real-world evidence. J Headache Pain 21(1):84","journal-title":"J Headache Pain"},{"issue":"1","key":"10523_CR33","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s10194-020-01127-0","volume":"21","author":"G Lambru","year":"2020","unstructured":"Lambru G, Hill B, Murphy M, Tylova I, Andreou AP (2020) A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain 21(1):61","journal-title":"J Headache Pain"},{"issue":"Suppl 1","key":"10523_CR34","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10072-019-03839-x","volume":"40","author":"P Barbanti","year":"2019","unstructured":"Barbanti P, Aurilia C, Egeo G, Fofi L (2019) Erenumab: from scientific evidence to clinical practice\u2014the first Italian real-life data. Neurol Sci 40(Suppl 1):177\u2013179","journal-title":"Neurol Sci"},{"issue":"1","key":"10523_CR35","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s10194-020-01157-8","volume":"21","author":"M Torres-ferrus","year":"2020","unstructured":"Torres-ferrus M, Gallardo VJ, Alpuente A, Pozo-rosich P (2020) Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA. J Headache Pain 21(1):88","journal-title":"J Headache Pain"},{"issue":"9","key":"10523_CR36","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1111\/head.13951","volume":"60","author":"J Robblee","year":"2020","unstructured":"Robblee J, Devick KL, Mendez N, Potter J, Slonaker J, Starling AJ (2020) Real-world patient experience with erenumab for the preventive treatment of migraine. Headache 60(9):2014\u20132025","journal-title":"Headache"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-021-10523-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-021-10523-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-021-10523-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T17:56:09Z","timestamp":1632506169000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-021-10523-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,27]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10523"],"URL":"https:\/\/doi.org\/10.1007\/s00415-021-10523-8","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,27]]},"assertion":[{"value":"2 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Marta Torres-Ferrus has received honoraria as a consultant or speaker for Allergan-Abbvie, Almirall, Chiesi, Eli Lilly, Novartis and Teva. Alpuente A has received honoraria from Allergan plc, Novartis, Chiesi. Cipres-Gine E has received honoraria from Eli Lilly, Novartis and Teva. Victor J and Caronna E reports no diclosures. Pozo-Rosich P has received honoraria as a consultant and speaker for: Allergan-Abbvie, Almirall, Amgen, Biohaven, Chiesi, Eli Lilly, Medscape, Neurodiem, Novartis and Teva. Her research group has received research grants from Allergan, and has received funding for clinical trials from Alder, Allergan-Abbvie, Electrocore, Eli Lilly, Novartis and Teva. She is a trustee member of the board of the International Headache Society, member of the Council of the European Headache Society. She is in the editorial board of Revista de Neurologia, associate editor for Cephalalgia, Headache, Neurologia, Frontiers of Neurology and The Journal of Headache and Pain. She is a member of the Clinical Trials Guidelines Committee of the International Headache Society. She has edited the Guidelines for the Diagnosis and Treatment of Headache of the Spanish Neurological Society. She is the founder of . Pozo-Rosich P does not own stocks from any pharmaceutical company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Subjects\u2019 consent was obtained according to the Declaration of Helsinki. The study was approved by Vall d\u2019Hebron Ethics Committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Patients gave their consent for participation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Patients gave their consent for publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}